FormularyThe formulary decisions your competitors
make next quarter —visible now.
Formulary parses FDA filings, patent cliffs, and pipeline catalogs into actionable drug-launch timelines — before the street prices them in.
Tabelecleucel · BLA Priority
Biosimilar Switch Window Open
ENHERTU + Pertuzumab · HER2+
PDUFA: 04/06/2026 · AML/ALL/MDS
48% First-in-Class · 52% Rare Disease
FORMULARY COMMAND TERMINAL v2.1
BUILT FOR
Hospital Pharmacy Directors
Compare Humira-to-biosimilar conversion rates across PBMs. Build P&T committee dossiers with 47 pre-built templates.
Managed-Care Pharmacists
PDUFA-date alerts 72 hours in advance. MOA overlap maps for therapeutic class reviews. Budget impact models included.
Biotech BD Leads
Monitor 412+ biosimilar candidates. Identify market entry windows. Deal flow signals from pipeline data.
// THE PROBLEM
The FDA never stops filing.
Neither does the noise.
3,494 goal-closing actions in FY2023. 1,690 submissions under active review right now. Every NDA, BLA, and ANDA matters — but not equally, and not right now.
↑ UNFILTERED FDA SUBMISSION STREAM
Adalimumab Biosimilar Switch
Patent Cliff: Open Since 01/2023
CVS converted 97% of Humira use to biosimilars by Aug 2024. OptumRx and Express Scripts following with private-label products. Current market split: 62% AbbVie / 38% biosimilar. Projected 50/50 within 6 months.
Switch window is now. 73 FDA-approved biosimilars. Formulary dossier template ready.
↑ ONE FORMULARY-READY INSIGHT
// INTELLIGENCE TIERS
What you see depends on
what tier you're on.
Free access proves the concept. Command Access closes the information gap.
NO CREDIT CARD · INSTITUTIONAL EMAIL REQUIRED · CANCEL ANYTIME
// PIPELINE INTELLIGENCE
Enough to prove depth.
Not enough to satisfy.
The intelligence gap between what you're seeing and what's redacted is exactly what Command Access closes.
Adalimumab Biosimilar Formulary Dossier
Orca-T Pipeline Intelligence Brief
Phase III Oncology Pipeline — Q2 2026 Readout Calendar
UNLOCK ONE FULL BRIEF
Preview a Sample Pipeline Brief
Institutional email + therapeutic area. No credit card. One full unredacted brief, delivered immediately.
Request Sample Brief →// COMMAND ACCESS
14-Day Command Access.
No credit card required.
Institutional email gets you full unredacted pipeline intelligence, biosimilar switch timelines, and formulary dossier templates — starting immediately.